Post-Cycle Therapy (PCT)
Restarting the HPG Axis After Androgen Suppression
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- No FDA-approved PCT protocol (off-label use of various drugs)
Reference only. Not medical advice.
What can go wrong
PCT addresses a problem created by suppressing the axis with anabolic agents in the first place. The drugs themselves carry risks (for example visual symptoms and mood effects with clomiphene, thromboembolic risk with tamoxifen) and are used off-label, often self-sourced and unmonitored. Recovery is not guaranteed; some users develop persistent hypogonadism requiring medical evaluation.
This is something to take to a clinician. The Atlas can tell you what is known about post-cycle therapy (pct) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Post-cycle therapy (PCT) is the bodybuilding-community practice of using drugs such as selective estrogen receptor modulators (clomiphene, tamoxifen), hCG, and sometimes aromatase inhibitors to restart endogenous testosterone production after a course of anabolic steroids or SARMs has suppressed the HPG axis. There is no FDA-approved PCT protocol, and the regimens are largely derived from community experience rather than rigorous clinical trials. Whether and how quickly the axis recovers varies, and some men experience prolonged or incomplete recovery.
An unapproved practice meant to undo self-inflicted suppression.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
SERMs like clomiphene and tamoxifen block estrogen feedback at the hypothalamus and pituitary, increasing GnRH, LH, and FSH and thereby stimulating the testes to resume testosterone production. hCG mimics LH to directly stimulate Leydig cells. The same mechanisms underlie legitimate medical fertility-restoration protocols, but PCT typically applies them without medical supervision after nonmedical androgen use.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration of off-label medications to restart the hormonal axis carries documented health risks.
Replacement is not the same as a cycle
PCT is not physiological replacement; it is an attempt to recover from the supraphysiological androgen exposure (anabolic steroids or SARMs) that suppressed the axis. The need for PCT is itself a marker that supraphysiological dosing has occurred, and the practice carries its own off-label medication risks without standardized, trial-validated protocols.
What it does to fertility
PCT is largely about restoring fertility and endogenous testosterone after suppression; success is variable and depends on the agents used, the prior compounds and doses, and individual physiology, with no guarantee of full recovery.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- LH, FSH, testosterone over time
- Estradiol
- Semen analysis where fertility is the goal
- Mood and visual symptoms on SERMs
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Set against the alternatives
PCT borrows from the same toolkit used in supervised treatment of secondary hypogonadism and male infertility, but differs in being self-directed, unmonitored, and aimed at reversing self-inflicted suppression rather than treating a primary disease.
At a glance
- Goal
- Restart LH/FSH and endogenous testosterone after suppression
- Typical agents
- Clomiphene, tamoxifen, hCG (all off-label here)
- Evidence base
- Weak; community-derived, not trial-validated
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Post-Cycle Therapy (PCT). A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Studies of SERMs and hCG for axis recovery / fertilityMultiple
Clomiphene and hCG can raise LH, FSH, and testosterone and aid recovery of spermatogenesis, but data specific to post-anabolic-steroid PCT regimens are limited